Development and characterization of candidate rotavirus vaccine strains derived from children with diarrhoea in Vietnam

Le, Luan Thi; Nguyen, Trang Van; Nguyen, Phuong Mai; Huong, Ngo Thu; Huong, Nguyen Thanh; Hanh, Tran B.; Ha, Dang N.; Anh, Đặng Đức; Gentsch, Jon R.; Wang, Yuhuan; Esona, Mathew D.; Glass, Roger I.; Steele, A. Duncan; Kilgore, Paul E.; Man, Nguyen Van; Jiang, Baoming; Hien, Nguyen Dang

doi:10.1016/j.vaccine.2009.08.086

Cited by 19 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 26 An alternate way forward for RoV vaccination in Vietnam would be through regional mass production of a generic vaccine, such as the live-attenuated monovalent G1P[8] (Rotavin-M1, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam) vaccine that has recently undergone trials in Vietnam. 27 , 28 This approach may reduce the cost of RoV immunization to the Vietnamese health service, permitting a greater national coverage and thus greater impact.…”

Section: Discussionmentioning

confidence: 99%

A Prospective Multi-Center Observational Study of Children Hospitalized with Diarrhea in Ho Chi Minh City, Vietnam

Thompson¹,

Phan²,

Hoàng³

et al. 2015

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

We performed a prospective multicenter study to address the lack of data on the etiology, clinical and demographic features of hospitalized pediatric diarrhea in Ho Chi Minh City (HCMC), Vietnam. Over 2,000 (1,419 symptomatic and 609 non-diarrheal control) children were enrolled in three hospitals over a 1-year period in 2009–2010. Aiming to detect a panel of pathogens, we identified a known diarrheal pathogen in stool samples from 1,067/1,419 (75.2%) children with diarrhea and from 81/609 (13.3%) children without diarrhea. Rotavirus predominated in the symptomatic children (664/1,419; 46.8%), followed by norovirus (293/1,419; 20.6%). The bacterial pathogens Salmonella, Campylobacter, and Shigella were cumulatively isolated from 204/1,419 (14.4%) diarrheal children and exhibited extensive antimicrobial resistance, most notably to fluoroquinolones and third-generation cephalosporins. We suggest renewed efforts in generation and implementation of policies to control the sale and prescription of antimicrobials to curb bacterial resistance and advise consideration of a subsidized rotavirus vaccination policy to limit the morbidity due to diarrheal disease in Vietnam.

show abstract

Section: Discussionmentioning

confidence: 99%

A Prospective Multi-Center Observational Study of Children Hospitalized with Diarrhea in Ho Chi Minh City, Vietnam

Thompson¹,

Phan²,

Hoàng³

et al. 2015

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

“…Nationally licensed vaccines can play an important role in broadening the affordability and availability of rotavirus vaccination, particularly in countries with the desire and ability to pursue local manufacture. For instance, in Vietnam, the government has made a concerted effort to foster the development and local manufacture of vaccines, to enable self-sufficiency [56]. Rotavirus-focused efforts led to the development of Rotavin-M1, a live, attenuated, frozen oral vaccine derived from a human rotavirus strain (G1P[8]) isolated from a child hospitalized for diarrhea in Nha Trang, Vietnam [56,57].…”

Section: Nationally Licensed Vaccinesmentioning

confidence: 99%

Current and new rotavirus vaccines

Burke

Tate

Kirkwood

et al. 2019

Current Opinion in Infectious Diseases

Self Cite

130

158

View full text Add to dashboard Cite

Purpose of reviewAs of 2019, four rotavirus vaccines have been prequalified by the WHO for use worldwide. This review highlights current knowledge regarding rotavirus vaccines available, and provides a brief summary of the rotavirus vaccine pipeline.Recent findingsData generated from use of currently available products supports their effectiveness and impact in diverse settings. Rotavirus vaccines have a favorable risk–benefit profile, but previous associations of rotavirus vaccination with intussusception necessitate continued monitoring for this rare but serious adverse event. Implementation of rotavirus vaccines was jeopardized in late 2018 and 2019 by a shortage of vaccine supply. Fortunately, with the prequalification of two additional vaccines in 2018, countries have increased choice in products with different characteristics, pricing, and implementation strategies. Other vaccines currently in development may open up further immunization strategies, such as neonatal vaccination schedules or parenteral administration.SummaryRotavirus vaccines have demonstrated impact in reducing diarrheal morbidity and mortality worldwide. As countries begin to introduce the newly prequalified vaccines, additional data will become available on the safety and effectiveness of those products. Products in the pipeline have distinct profiles and could be an essential part of the expansion of rotavirus vaccine use worldwide.

show abstract

“…Three human rotavirus strains (genotypes G1P[8], G1P[4], and G4P[6]) have been characterized for potential use in a live attenuated vaccine 105. The wild-type viruses for these strains have been passed more than 30 times, each through cell culture with the goal of developing an effective indigenously produced vaccine.…”

Section: Rotavirus Vaccinesmentioning

confidence: 99%

Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines

Chandran¹,

Fitzwater²,

Zhen³

et al. 2010

BTT

View full text Add to dashboard Cite

Rotavirus infection is the most common cause of severe gastroenteritis globally, with greater than 86% of deaths occurring in low-income and middle-income countries. There are two rotavirus vaccines currently licensed in the United States and prequalified by the World Health Organization. RV1 is a monovalent attenuated human rotavirus strain, given orally in two doses. RV5 is a pentavalent human-bovine reassortant rotavirus vaccine, given orally in three doses. A third rotavirus vaccine, LLV, is a lamb rotavirus strain given orally as a single dose, which is currently available only in China. RV1 and RV5 have been shown to be highly efficacious in developed countries, and initial results from trials in Africa and Asia are promising as well. At least three other vaccines are in development, which are being developed by manufacturers of developing countries. Further studies are needed to clarify issues including administration of oral rotavirus vaccines with breastfeeding and other oral vaccines, and alterations in dosing schedule. Using new data on global diarrheal burden, rotavirus is estimated to cause 390,000 deaths in children younger than 5 years. Should rotavirus vaccines be introduced in the routine immunization programs of all countries, a potential of 170,000 deaths could be prevented annually. The largest impact on mortality would be seen in low-income and middle-income countries, despite poor immunization coverage and lower efficacy. Therefore, international efforts are needed to ensure that rotavirus vaccines reach the populations with highest burden of rotavirus disease.

show abstract

Development and characterization of candidate rotavirus vaccine strains derived from children with diarrhoea in Vietnam

Cited by 19 publications

References 13 publications

A Prospective Multi-Center Observational Study of Children Hospitalized with Diarrhea in Ho Chi Minh City, Vietnam

A Prospective Multi-Center Observational Study of Children Hospitalized with Diarrhea in Ho Chi Minh City, Vietnam

Current and new rotavirus vaccines

Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines

Contact Info

Product

Resources

About